Literature DB >> 25337247

LSF expression and its prognostic implication in colorectal cancer.

Hui Jiang1, Jun Du1, Jianqiang Jin2, Xiaowei Qi2, Yong Pu2, Bojian Fei3.   

Abstract

Colorectal cancer (CRC) is the third most common cancer worldwide and the fourth most common cause of cancer death. Therapy failure was the first cause of death. LSF is a transcription factor regulating gene expression of angiogenesis, tumor invasion and proliferation, and is identified as a chemoresistant gene. Real-time PCR and Western blot to analyze mRNA and protein expression of LSF in 23 paired CRC samples. Immunohistochemistry was used to detect protein expression of LSF in 166 paired CRC samples. Both LSF mRNA and protein were upregulated in CRC. High LSF expression in CRC correlated with large tumor size, advanced pN stage, advanced AJCC stage and high Ki-67 index (P < 0.001). High expression of LSF favored worse prognosis. 5-year survival rates of LSF high and low expression were 39.6% and 78.6%, respectively. The 5-year median OS were 34 months and 57 months, respectively. LSF is an important mediator in CRC tumorigenesis and progression, and LSF expression is an important index for and prognostic prediction.

Entities:  

Keywords:  LSF; colorectal cancer; prognosis

Mesh:

Substances:

Year:  2014        PMID: 25337247      PMCID: PMC4203218     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  20 in total

Review 1.  Molecular genetics of colorectal cancer.

Authors:  Eric R Fearon
Journal:  Annu Rev Pathol       Date:  2011       Impact factor: 23.472

Review 2.  NF-kappaB signaling pathway, inflammation and colorectal cancer.

Authors:  Soly Wang; Zhanjie Liu; Lunshan Wang; Xiaoren Zhang
Journal:  Cell Mol Immunol       Date:  2009-10       Impact factor: 11.530

3.  Colorectal cancer prognosis twenty years later.

Authors:  Luis Bujanda; Cristina Sarasqueta; Elisabeth Hijona; Lander Hijona; Angel Cosme; Ines Gil; Jose Luis Elorza; Jose I Asensio; Santiago Larburu; José M Enríquez-Navascués; Rodrigo Jover; Francesc Balaguer; Xavier Llor; Xavier Bessa; Montserrat Andreu; Artemio Paya; Antoni Castells
Journal:  World J Gastroenterol       Date:  2010-02-21       Impact factor: 5.742

4.  Late SV40 factor: a key mediator of Notch signaling in human hepatocarcinogenesis.

Authors:  Ren-Hua Fan; Jing Li; Nan Wu; Ping-Sheng Chen
Journal:  World J Gastroenterol       Date:  2011-08-07       Impact factor: 5.742

5.  The human factors YY1 and LSF repress the human immunodeficiency virus type 1 long terminal repeat via recruitment of histone deacetylase 1.

Authors:  J J Coull; F Romerio; J M Sun; J L Volker; K M Galvin; J R Davie; Y Shi; U Hansen; D M Margolis
Journal:  J Virol       Date:  2000-08       Impact factor: 5.103

Review 6.  Lineage-specific and ubiquitous biological roles of the mammalian transcription factor LSF.

Authors:  Jelena Veljkovic; Ulla Hansen
Journal:  Gene       Date:  2004-12-08       Impact factor: 3.688

7.  The transcription factor LSF: a novel oncogene for hepatocellular carcinoma.

Authors:  Prasanna K Santhekadur; Devaraja Rajasekaran; Ayesha Siddiq; Rachel Gredler; Dong Chen; Scott E Schaus; Ulla Hansen; Paul B Fisher; Devanand Sarkar
Journal:  Am J Cancer Res       Date:  2012-04-21       Impact factor: 6.166

Review 8.  Small integrin-binding ligand N-linked glycoproteins (SIBLINGs): multifunctional proteins in cancer.

Authors:  Akeila Bellahcène; Vincent Castronovo; Kalu U E Ogbureke; Larry W Fisher; Neal S Fedarko
Journal:  Nat Rev Cancer       Date:  2008-03       Impact factor: 60.716

9.  Therapy of refractory/relapsed acute myeloid leukemia and blast crisis of chronic myeloid leukemia with the combination of cytosine arabinoside, tetrahydrouridine, and carboplatin.

Authors:  J H Marsh; W Kreis; B Barile; S Akerman; P Schulman; S L Allen; L C DeMarco; M W Schuster; D R Budman
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

10.  Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy.

Authors:  Bret B Friday; Alex A Adjei
Journal:  Clin Cancer Res       Date:  2008-01-15       Impact factor: 12.531

View more
  11 in total

1.  Chemopreventive efficacy of stampidine in a murine breast cancer model.

Authors:  Kazim Sahin; Cemal Orhan; Ibrahim Hanifi Ozercan; Mehmet Tuzcu; Birsen Elibol; Taha Koray Sahin; Ulkan Kilic; Sanjive Qazi; Fatih Mehmet Uckun
Journal:  Expert Opin Ther Targets       Date:  2020-02-05       Impact factor: 6.902

2.  Pharmacologic Manipulation of Late SV40 Factor Suppresses Wnt Signaling and Inhibits Growth of Allogeneic and Syngeneic Colon Cancer Xenografts.

Authors:  Saran Lotfollahzadeh; Dominic Lo; Emily A York; Marc A Napoleon; Wenqing Yin; Nagla Elzinad; John Le; Mengwei Zhang; Xiaosheng Yang; Austin Morrissey; Murad Elsadawi; Qing Zhao; Scott E Schaus; Ulla Hansen; Vipul C Chitalia
Journal:  Am J Pathol       Date:  2022-06-13       Impact factor: 5.770

3.  Factor quinolinone inhibitors disrupt spindles and multiple LSF (TFCP2)-protein interactions in mitosis, including with microtubule-associated proteins.

Authors:  Sarah A Yunes; Jennifer L S Willoughby; Julian H Kwan; Jessica M Biagi; Niranjana Pokharel; Hang Gyeong Chin; Emily A York; Kuan-Chung Su; Kelly George; Jagesh V Shah; Andrew Emili; Scott E Schaus; Ulla Hansen
Journal:  PLoS One       Date:  2022-06-15       Impact factor: 3.752

4.  MAGE-A11 is activated through TFCP2/ZEB1 binding sites de-methylation as well as histone modification and facilitates ESCC tumor growth.

Authors:  Shina Liu; Fei Liu; Weina Huang; Lina Gu; Lingjiao Meng; Yingchao Ju; Yunyan Wu; Juan Li; Lihua Liu; Meixiang Sang
Journal:  Oncotarget       Date:  2017-12-05

5.  Diagnostic and prognostic relevance of CP2c and YY1 expression in hepatocellular carcinoma.

Authors:  Ji Sook Kim; Seung Han Son; Min Young Kim; DongHo Choi; Ik-Soon Jang; Seung Sam Paik; Ji Hyung Chae; Vladimir N Uversky; Chul Geun Kim
Journal:  Oncotarget       Date:  2017-04-11

6.  TFCP2 Genetic Polymorphism Is Associated with Predisposition to and Transplant Prognosis of Hepatocellular Carcinoma.

Authors:  Zhikun Liu; Feng Gao; Zhou Shao; Haiyang Xie; Lin Zhou; Xiao Xu; Shusen Zheng
Journal:  Gastroenterol Res Pract       Date:  2017-02-27       Impact factor: 2.260

7.  Transcription factors CP2 and YY1 as prognostic markers in head and neck squamous cell carcinoma: analysis of The Cancer Genome Atlas and a second independent cohort.

Authors:  Julia Schnoell; Bernhard J Jank; Lorenz Kadletz-Wanke; Stefan Stoiber; Clemens P Spielvogel; Elisabeth Gurnhofer; Lukas Kenner; Gregor Heiduschka
Journal:  J Cancer Res Clin Oncol       Date:  2020-12-14       Impact factor: 4.553

8.  Integrating transcriptional and protein interaction networks to prioritize condition-specific master regulators.

Authors:  Megha Padi; John Quackenbush
Journal:  BMC Syst Biol       Date:  2015-11-14

9.  Implication of the APP Gene in Intellectual Abilities.

Authors:  Craig Myrum; Oleksii Nikolaienko; Clive R Bramham; Jan Haavik; Tetyana Zayats
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

10.  TFCP2 activates beta-catenin/TCF signaling in the progression of pancreatic cancer.

Authors:  Dai Yuedi; Cai Yuankun; Zhao Jiaying; Liu Han; Wang Yueqi; Liu Houbao; Zhang Dexiang
Journal:  Oncotarget       Date:  2017-07-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.